Honasa Consumer scraps 58% Fluence Pharma stake acquisition
Key Takeaways
- •Honasa Consumer has called off its proposed acquisition of a 58% stake in Fluence Pharma.
- •The deal was scrapped because the closing conditions under the share purchase agreement were not fulfilled.
- •Honasa did not provide any additional explanation for why the conditions were not met.
- •The company said it will keep evaluating both organic and inorganic opportunities in the nutraceuticals segment.
- •Honasa indicated that its broader nutraceutical strategy remains unchanged despite the terminated transaction.
Honasa Consumer scraps 58% Fluence Pharma stake acquisition
Honasa Consumer, the parent company of Mamaearth, has called off its proposed acquisition of a 58% stake in Fluence Pharma after the closing conditions under the share purchase agreement were not fulfilled.
The FMCG company said it will continue to evaluate both organic and inorganic opportunities in the nutraceuticals segment, keeping that category in focus even as this transaction is discontinued.
FMCG firm to continue nutraceutical strategy
Honasa did not provide additional details on why the closing conditions were not met.
The update matters because nutraceuticals have become an active expansion area for consumer companies looking to widen their health and wellness portfolios, and Honasa’s statement indicates that the broader strategy remains unchanged despite the deal being scrapped.
